Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Thermo Fisher Scientific (TMO)

Thermo Fisher Q2 revenue rises 10% to $11.99 billion; adjusted EPS up 13%

Positive Impact 3 of 5 earnings Written later

Thermo Fisher reported second-quarter 2026 results for the quarter ended June 27, with revenue up 10% to $11.99 billion, including 5% organic growth. GAAP diluted EPS rose 9% to $4.68 and adjusted EPS rose 13% to $6.03. The company said it will provide updated 2026 guidance on its earnings call that morning, so the new outlook is not in the filing.

Key points

  • Q2 revenue was $11.99 billion versus $10.85 billion a year earlier; organic growth was 5%.
  • GAAP operating income was $2.09 billion, up 14%, with operating margin at 17.4% versus 16.9%.
  • The company repurchased $1.0 billion of stock during the quarter and announced the divestiture of its microbiology business.

The filing

CompanyThermo Fisher Scientific (TMO)
Form8-K, current report
Filed with the SECJul 23, 2026, 6:04 AM ET
Accession number0000097745-26-000138

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.